Closed · HT9425-23-TBIPHRP-HSRA · CFDA 12.420 · Discretionary

DoD Traumatic Brain Injury and Psychological Health, Health Services Research Award

Federal grant opportunity posted by Dept. of the Army -- USAMRAA, cataloged on Grants.gov.

Varies
Award range
Closed
Status
July 6, 2023
Close date
8
Expected awards

The verdict

DoD Traumatic Brain Injury and Psychological Health, Health Services Research Award is a closed discretionary listing from Dept. of the Army -- USAMRAA that offered Varies by applicant across 8 expected awards. Future funding cycles may be published under the same CFDA number.

Varies
award range
Closed
application status
8
expected awards
12.420
CFDA program

Opportunity snapshot. This Grants.gov announcement - DoD Traumatic Brain Injury and Psychological Health, Health Services Research Award - is cataloged under number HT9425-23-TBIPHRP-HSRA and tied to CFDA assistance listing 12.420, posted by Dept. of the Army -- USAMRAA. Grants.gov currently shows the opportunity as closed, first posted on April 27, 2023 and last updated on May 12, 2023. The funding category is Discretionary, delivered as a grant.

Award economics. The award range on file is Varies by applicant. The agency has projected $18.6 million in total estimated funding for this announcement. It expects to issue 8 awards. If the agency funds the expected 8 awards from the $18.6 million estimated pool, the average award works out to roughly $2.3 million. Cost sharing is not required, so applicants do not need to commit matching funds to be competitive on this opportunity. Federal award ranges are often upper bounds; actual allocations reflect program appropriations, the strength of the applicant pool, and the evaluation committee's scoring.

Deadline and action path. This opportunity closed on July 6, 2023. Future funding cycles may be published under the same CFDA number, so monitoring the parent program page is the most reliable way to catch re-announcements. Every Grants.gov submission requires an active SAM.gov registration and a Unique Entity ID. Review the Eligibility section below carefully, federal eligibility categories (nonprofit, state or local government, tribal, individual, educational institution, small business) have distinct registration and reporting requirements. Pre-application outreach to the listed agency contact is permitted and often welcomed, it helps clarify scope and scoring priorities. Before acting on the deadline or award figures above, verify them directly on the official Grants.gov listing, amendments can change dates and amounts after this page was last refreshed.

Award Range

Varies by applicant

Close Date

July 6, 2023

Posted

April 27, 2023

Est. Total Funding

$18,600,000

Expected Awards

8

Instrument

Grant

Description

Maturing research ideas into clinical practice and patient benefit is at the heart of all CDMRP research programs. Despite significant investment, the gap between what is possible and what is achieved remains. Even after information, tools, and interventions have been successfully evaluated in their intended populations, the development of knowledge to support their broader dissemination and implementation has often remained outside the scope.The FY23 TBIPHRP HSRA intends to bridge the gap between research, practice, and policy by building a knowledge base on how interventions, clinical practices/guidelines, tools, and policies can be deployed to targeted populations at the appropriate time at the point of need. Funding from this award mechanism must support clinical research or clinical trials but cannot be used for preclinical or animal research. Applications may propose prospective or retrospective research involving human subjects, human subject data/records, and human anatomical substances. This award may not be used to support studies requiring an exception from informed consent (EFIC).The FY23 HSRA may support (not all inclusive):• Research that accelerates the uptake and implementation of evidence-based research into clinical practice.• Comparative effectiveness research comparing the benefits and harms of emerging or established interventions and strategies to prevent, diagnose, treat, and monitor health conditions in “real-world” settings• Development and evaluation of strategies to overcome barriers to the adoption, adaptation, integration, scale-up, and sustainability of evidence-based interventions, tools, policies, and guidelines• Analysis of existing data or resources to inform clinical practice• Modification of established clinical tools for their intended population or environment• Analysis of existing clinical tools to maximize patient-relevant outcomes• Identification and analysis of the circumstances that create a need to stop or reduce (“de-implement”) the use of interventions, tools, policies, and guidelines hat are ineffective, unproven, low-value, or harmful are within scope• Analysis of TBI and/or psychological health outcomes associated with the implementation of clinical practice guidelines, evidence-based practices, and process improvementsThe following are important aspects of the FY23 TBIPHRP HSRA:• Precision Medicine Approaches: When appropriate, the TBIPHRP encourages the use of precision medicine approaches. These tailored treatments deliver the right treatment at the right time while considering an individual’s unique characteristics.• Community-Based Participatory Research: The application must include Community- Based Participatory Research (CBPR) approaches in the development and execution of the clinical research/trial. CBPR approaches should be documented in Attachments 11 and 12.• Preliminary data are required: Inclusion of preliminary data relevant to the proposed clinical research/trial is required.• Study Population: The application should demonstrate the availability of and access to a suitable patient population that will support a meaningful outcome for the study. The application should include a discussion of how accrual goals will be achieved, as well as the strategy for inclusion of women and minorities in the clinical trial appropriate to the objectives of the study. Studies utilizing human biospecimens or datasets that cannot be linked to a specific individual, gender, ethnicity, or race (typically classified as exempt from Inquiry Review Board [IRB] review) are exempt from this requirement.• Clinical Trial Start Date: If applicable, the proposed clinical trial is expected to begin no later than 6 months after the award date.• Intervention Availability: If applicable, the application should demonstrate the documented availability of and access to the drug/compound, device, and/or other materials needed, as appropriate, for the proposed duration of the study.A clinical trial is defined as a research study in which one or more human subjects are prospectively assigned to one or more interventions (which may include a placebo or another control) to evaluate the effects of the interventions on biomedical or behavioral health-related outcomes.Funded clinical trials are required to post a copy of the informed consent form used to enroll subjects on a publicly available federal website in accordance with federal requirements described in the Code of Federal Regulations, Title 32, Part 219 (32 CFR 219). Funded trials are required to register the study in the National Institutes of Health (NIH) clinical trials registry, www.clinicaltrials.gov, prior to initiation of the study. Refer to the General Application Instructions, Appendix 1, Section B, for further details.Studies that do not seek to measure safety, effectiveness, and/or efficacy outcome(s) of an intervention are not considered clinical trials.Clinical research encompasses research with patient samples, data, and interaction with patients that may or may not be considered a clinical trial. For the purposes of this funding opportunity, research that meets the definition of a clinical trial is distinct from clinical research. Clinical research is observational in nature and includes: (1) Research that does not seek to evaluate the effects of interventions. Research conducted with human subjects (or on material of human origin such as data, tissues, specimens, and cognitive phenomena) for which an investigator (or colleague) directly interacts with human subjects, but does not seek to assess the effects of an intervention, qualifies as clinical research. Patient-oriented research may include but is not limited to: (a) mechanisms of human disease, (b) diagnostic or detection studies (e.g., biomarker or imaging), (c) health disparity studies, and (d) development of new technologies.(2) Epidemiologic and behavioral studies that do not seek to study the safety, effectiveness, and/or efficacy outcomes of an intervention. (3) Outcomes research and health services research that do not fit under the definition of clinical trial. Excluded from the definition of clinical research are in vitro studies that utilize human tissues that cannot be linked to a living individual. Note: Studies that meet the requirements for exemption under §46.104(d)(4) of the Common Rule are not considered clinical research as defined by CDMRP. Exemption category 4 refers to secondary research for which consent is not required.

Eligibility

Grants.gov lists this opportunity under eligibility category code 99. These codes correspond to applicant types (state/local government, tribal organization, nonprofit, educational institution, individual, small business, etc.) defined in Grants.gov's own eligibility reference. See the current Grants.gov eligibility categories or check the official listing below for this opportunity's exact eligibility statement.

Official Listing on Grants.gov

View full details, application forms, and submission instructions.

View on Grants.gov

Agency Contact

CDMRP Help Desk Phone: 301-682-5507 Email: help@eBRAP.org

Key Dates

Posted April 27, 2023
Close Date July 6, 2023
Archive Date August 5, 2023
Last Updated May 12, 2023

Frequently Asked Questions

What is this grant opportunity?
This is a federal funding opportunity titled "DoD Traumatic Brain Injury and Psychological Health, Health Services Research Award", offered by Dept. of the Army -- USAMRAA. It is associated with CFDA program 12.420. Maturing research ideas into clinical practice and patient benefit is at the heart of all CDMRP research programs. Despite significant investment, the gap between what is possible and what is achieved...
Is this opportunity still open?
No, this opportunity is closed. It closed on July 6, 2023. Check the parent program page for future funding cycles.
How much funding is available?
The award range for this opportunity is Varies by applicant. Total estimated funding: $18,600,000. Expected number of awards: 8.
How do I apply?
Applications for federal grant opportunities are typically submitted through Grants.gov. Visit the official listing at grants.gov for application instructions, required documents, and submission deadlines.

Disclaimer: This information is sourced from Grants.gov and SAM.gov and is for informational purposes only. Opportunity details, deadlines, and eligibility requirements change frequently. Always verify current information directly on Grants.gov before applying. PlainGrants is not affiliated with any federal agency.

Data sourced from the SAM.gov Assistance Listings and Grants.gov. See our methodology for details. Retrieved and formatted by PlainGrants